We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

In the latest quarter, 8 analysts provided ratings for Vertex (NASDAQ:VERX), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%. Vertex’s earnings surpassed the Zacks ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Vertex, Inc. (NASDAQ:VERX – Free Report) – Stock analysts at DA Davidson decreased their FY2025 earnings estimates for shares of Vertex in a research report issued to clients and investors on ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...